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1. Introduction 
Mitochondria are dynamic subcellular organelles present in virtually all eukaryotic cells 
with numerous functions. The most important of these functions is production of ATP; 
however they play an important role in various metabolic and developmental processes 
such as calcium homeostasis, apoptosis and programmed cell death, just to mention some. 
Mitochondria produce ATP by means of the mitochondrial respiratory chain (MRC) and 
oxidative phosphorylation (OXPHOS) system, a series of five enzyme complexes embedded 
in the inner mitochondrial membrane. Mitochondrial disorders most often refer to the 
dysfunction of OXPHOS system leading to deficiency in the ATP production. They are a 
group of genetically and phenotypically heterogeneous disorders with an incidence 
estimated to be between 1:5,000 and 1:10,000 live births [1]. 
MRC is the result of the interplay of two physically and functionally separated genomes, the 
nuclear DNA (nDNA) and mitochondrial DNA (mtDNA). Thirteen of the key structural 
polypeptides that constitute the multimeric subunits of the respiratory chain complexes are 
mtDNA encoded, in addition two ribosomal RNA (rRNA) and 22 transfer RNA (tRNA) that 
are required for initiating translation and protein synthesis [2]. Approximately 90 of the 
remaining proteins that make up the respiratory chain complexes are encoded by nDNA. 
Therefore, although human mtDNA encodes the basic machinery for protein synthesis, it 
depends entirely on the nucleus for the provision of enzymes for replication, repair, 
transcription, and translation. This dependency lies at the heart of several newly recognized 
human diseases that are characterized by secondary abnormalities of mtDNA.  
The crosstalk between the two genomes is crucial for the cellular regulation of mtDNA 
integrity and copy number and correct mitochondrial protein production therefore 
mutations in genes involved in mitochondrial replication and maintenance can disrupt the 
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integrity of the mitochondrial genome, causing inter-genomic communication disorders. 
Multiple deletions, depletion of mtDNA or a combination of both phenomena 
(qualitative/quantitative lesions) in critical tissues, are the hallmarks of these disorders.  
The focus of this chapter is to review the clinical and molecular etiologies of nuclear defects 
involved in mtDNA stability and in mitochondrial protein synthesis. The overview done 
here will hopefully provide insights towards best diagnostic strategies of mitochondrial 
cross–talk disorders, being useful for clinicians when facing similar cases. Additionally we 
will present a diagnostic algorithm for these diseases based on our knowledge. 
2. Clinical manifestations of disorders affecting mtDNA integrity 
Maintenance of mtDNA is controlled by an intricate homeostatic network, whose effectors 
are the various components of the mitochondrial replicosome and the many enzymes and 
carrier proteins that provide the mitochondrion with a balance supply of 
deoxyribonucleotides (Figure 1). As all of the factors are nDNA encoded, it is not surprising 
that mutations in genes involved in mitochondrial replication and maintenance can disrupt 
the integrity of the ‘‘tiny’’ mitochondrial genome [3] leading to multiple deletions or 
depletion [4]. The mitonuclear crosstalk has gained increased relevance in the past years and 
since then many genes have been identified as being involved in these diseases. 
In the following section we will briefly review the clinical manifestations of both these 
group of disorders. 
2.1. mtDNA multiple deletion syndromes 
Mitochondrial diseases associated with the presence of multiple deletions of mtDNA are 
mostly autosomal dominant, occurring most often in adulthood. The size and terminals 
deletions are variable from one individual to another within the same family.  
The main clinical manifestations associated with multiple deletions are: 
i. PEO (autosomal dominant or recessive Progressive External Ophthalmoplegia). The 
most common clinical features include adult-onset of weakness of the external eye 
muscles, bilateral ptosis, proximal muscle weakness wasting and exercise intolerance. 
Additional symptoms are variable, and may include cataracts, hearing loss, sensory 
axonal neuropathy, ataxia, depression, hypogonadism, and Parkinsonism. Less 
common features include mitral valve prolapse, cardiomyopathy, and gastrointestinal 
dysmotility. Both autosomal dominant and autosomal recessive inheritance can occur; 
autosomal recessive inheritance is usually more severe [5,6]. The multiple deletions 
associated with PEO are exclusively found in muscle tissues of patients. 
ii. SANDO (Sensory Ataxic Neuropathy, Dysarthria and Ophthalmoparesis) is an 
autosomal recessive systemic disorder characterized mainly by adult onset of sensory 
ataxic neuropathy, dysarthria, and ophthalmoparesis. The phenotype varies widely, 
even within the same family, and can include myopathy, seizures, and hearing loss, but 
the common clinical feature appears to be sensory ataxia [7].  
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Figure 1. Schematic overview of the mitochondrion and the mitochondrial disease genes involved in 
intergenomic communication disorders. Zooming in on the mitochondrion allows identification of 
genes (namely, POLG and C10orf2- Twinkle) thought to be involved in replication of mitochondrial DNA 
(mtDNA); those assumed to affect the metabolism of the mitochondrial deoxynucleotide (dNTP) pool 
(via progressive phosphorylations of deoxythymidine, deoxycytidine, deoxytadenine, and 
deoxiguanosine); and those belonging to the tricarboxylic acid cycle and affecting the respiratory chain 
complexes (OXPHOS). Moreover, the supposed role of genes involved in the complex machinery of 
mitochondrial protein synthesis (including the aminoacyl-tRNA synthetases) is illustrated. This figure 
was kindly provided by Prof. Filippo M. Santorelli. 
iii. MNGIE (Mitochondrial NeuroGastroIntestinal Encephalomyopathy), an autosomal 
recessive disorder clinically characterized by onset between the second and fifth 
decades of life, PEO, gastrointestinal dysmotility (often pseudo-obstruction), cachexia, 
diffuse leukoencephalopathy, peripheral neuropathy and early death. Mitochondrial 
DNA abnormalities can include depletion, multiple deletions, and point mutations [8]. 
iv. SCAE (SpinoCerebellar Ataxia – Epilepsy syndrome) disorder similar to SANDO but 
with a higher frequency of migraine headaches and seizures [9]. 
2.2. mtDNA depletion syndromes 
Quantitative alterations are characterized by depletion of mtDNA. Mitochondrial DNA 
depletion syndrome (MDS) comprises a heterogeneous group of autosomal recessive 
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disorders, all having the same molecular end result, low mtDNA amount in specific tissues. 
MDS are a group of rare and devastating diseases that manifest typically, although not 
exclusively, soon after birth, determining early death usually in infancy or early childhood. 
MDS differs from other respiratory chain disorders, as most often it may manifest solely in a 
specific organ (most commonly muscle or liver) [10]. However, it may occur that multiple 
organs, including heart, brain, and kidney are affected [11]. An extensive review on MDS 
was recently published [12]. 
Three major clinical categories can be recognized however, the clinical phenotypes are 
heterogeneous, overlapping and ever expanding [10,13]:  
i. Hepatocerebral MDS is most probably the most common variant of MDS; Onset of 
symptoms is between birth and 6 months; death usually occurs within one year of age. 
The most common symptoms and signs include persistent vomiting, failure to thrive, 
hypotonia and hypoglycemia associated with progressive neurological symptoms. 
Histological changes on liver biopsy include fatty degeneration, bile duct proliferation, 
fibrosis, and collapse of lobular architecture. Reduced COX histochemistry and 
combined deficiency of mtDNA encoded MRC complexes were found in the liver of a 
few patients.  
A peculiar form of hepatocerebral MDS is Alpers-Huttenlocher syndrome, an early 
onset, fatal disease, characterized by hepatic failure, intractable seizures, evolving into 
epilepsia partialis continua, and global neurological deterioration. The liver dysfunction is 
usually progressive as well, evolving from microvesicular staetosis with bile duct 
proliferation into cirrhosis and chronic liver failure. 
ii. Myopathic MDS typically onset of symptoms usually occur in the first year of life 
with feeding difficulty, failure to thrive, hypotonia, muscle weakness and 
occasionally PEO. Death is usually due to pulmonary insufficiency and infections,  
but some patients survive into their teens [14,15]. Muscle biopsy may show 
proliferation of mitochondria, which can increase with age, and patchy or diffuse 
COX deficiency. Biochemical defects of all mtDNA-related respiratory chain 
complexes are always present in muscle mitochondria. Serum CK levels may be 
variably elevated [4]. 
iii. Encephalomyopathic MDS is characterized by infantile onset of hypotonia with severe 
psychomotor retardation, high lactate in blood, progressive neurologic deterioration, a 
hyperkinetic-dystonic movement disorder, external ophthalmoplegia, deafness, 
generalized seizures and variable renal tubular dysfunction. Brain MRI was suggestive 
of Leigh syndrome [11]. 
3. Molecular etiologies of disorders affecting mtDNA integrity 
In the next sections we will mention the genes identified so far, to be responsible with these 
disorders. Table 1 summarizes the mutations described and the associated phenotypes. 
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Gene Phenotype 
Mutation Type  
M/N Sp Sd Si Sid Gd Gi Gr 
POLG 
PEO 61  1 2     
Alpers 37 5 2 6 2 3   
MDS 6  1      
Encephalopathy 3        
Mitochondrial spinocerebellar ataxia 
and epilepsy 
1        
SANDO 1   1     
POLG deficiency 29 1 2 2     
OXPHOS deficiency 2        
Ataxia 6 1       
Epilepsy 2  1      
Complex I deficiency 1        
Others 18 1       
POLG2 
PEO 1        
Mitochondrial disease 7  1    1  
SLC25A4 
PEO 5        
Mitochondrial myopathy & 
hypertrophic cardiomyopathy 
1 1 1 1     
SLC25A3 
Muscular hypotonia & hypertrophic 
cardiomyopathy 
1 1       
C10orf2 
PEO 34    1  1  
MDS 1        
Spirocerebellar ataxia, infantile onset 2        
Cholestatic liver disease 1        
Encephalopathy 1        
Ocular myopathy 1        
Complex I deficiency 1        
Dementia 1        
Reduced expression 1        
Tymp MNGIE 47 11 11 6 1    
TK2 
MDS 20 1 2 9 1 1  1 
Epileptic encephalomyopathy    1     
MDS with hearing loss    1     
PEO 1        
DGUOK MDS 28 6 9 4  1   
RRM2B 
MDS 12 2 1      
PEO 7  1 1     
MNGIE 2        
KSS 1        
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Gene Phenotype 
Mutation Type  
M/N Sp Sd Si Sid Gd Gi Gr 
Altered p53 binding, association with  1       
MPV17 
MDS – hepatocerebral 7 1 1  1 2   
Liver failure in infancy   2      
Lethal hepatopathy & 
leukodystrophy 
 1       
SUCLA2 
MDS – encephalomyopatic & 
methylmalonic ac. 
4 1   1   1 
SUCLG1 
Succinyl-coenzyme A synthetase 
deficiency 
4 1 1      
Lactic acidosis with mitochondrial 
DNA depletion 
2  1      
Neonatal lactic acidosis with 
methylmalonic aciduria 
2        
Lactic acidosis, fatal infantile  1       
Mitochondrial 
hepatoencephalomyopathy 
1        
PUS1 
Mitochondrial myopathy and 
sideroblastic anaemia 
2        
Sideroblastic anaemia 1        
TRMU 
Infantile liver failure, increased risk 6 1 1      
Combined OXPHOS deficiency    2     
Phenotype modifier 1        
Respiratory chain deficiency, 
reversible infantile 
 1       
LRPPRC Cytochrome c oxidase deficiency 1    1    
TACO1 Cytochrome c oxidase deficiency    1     
TUFM Combined OXPHOS deficiency 1        
TSFM Combined OXPHOS deficiency 2        
GFM1 Combined OXPHOS deficiency 8  2      
MRPS16 MRC disorder 1        
RARS2 Pontocerebellar hypoplasia 3 1 1      
DARS2 
Leukoencephalopathy, brain & spine 
involvement, lactate elevation 
15 11 1  2 1   
Episodic ataxia, exercise-induced 1        
YARS2 MLASA syndrome 1        
Table 1. Mutations types described in genes involved in mtDNA integrity and mitochondrial 
translation and associated clinical phenotype (M/N- missense/nonsense; Sp- splicing; Sd- small 
deletions; Si- small insertions; Sid- small inddels; Gd- gross deletions; Gi- gross insertions; Gr- gross 
rearrangements) - source HGMD Professional database www.hgmd.cf.ac.uk/. 
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3.1. Genes involved in mitochondrial replisome 
3.1.1. POLG 
Human mitochondria contain a single DNA polymerase, Polymerase gamma (POLγ), 
nuclear encoded and solely responsible for mtDNA replication and repair in mitochondria. 
POLγ is composed of a catalytic subunit, POLγA, which possesses both polymerase  
and proofreading exonuclease activities and an accessory subunit, POLγB, which increases 
enzyme processivity [16]. The POLγ holoenzyme functions in conjunction with  
the mitochondrial DNA helicase and the mitochondrial single-stranded DNA- binding 
protein to form the minimal replication apparatus [17]. It was generally accepted that 
mutations within the mtDNA were the major cause of mitochondrial diseases; however this 
view is changing as several of these have been linked to ineffective mtDNA replication by 
POLγ.  
Mutations affecting the catalytic subunit POLγA, encoded by the nuclear gene POLG are a 
major cause of mitochondrial disease, being highly heterogeneous – PEO, Parkinsonism, 
AHS, MNGIE, SANDO and SCAE- and usually is associated with multiple mtDNA 
deletions [18]. POLG mutations have been shown to be associated with all types of 
inheritance. The unique features of mitochondrial physiology are in part responsible for this 
variability but POLG structure and function add to the riddle of how one gene product can 
demonstrate autosomal recessive and autosomal dominant transmission. POLγA is a key 
player in mtDNA maintenance that is absolutely necessary for mtDNA replication from an 
early stage in embryogenesis [19]  
In adPEO due to POLG mutations (most frequent), prominent features are severe dysphagia 
and dysphonia, and, occasionally, a movement disorder including Parkinsonism, cerebellar 
dysfunction, and chorea. Recessive mutations of POLG are responsible for sporadic and 
arPEO, as well as the syndromes referred above. Mutations in this gene can be also 
associated to the hepatocerebral form of MDS, namely AHS [18]. 
The POLG gene is located at chromosome 15, comprises 23 exons spanning 18.55 Kb. The 
gene was identified in 1996 [20] but only in 2001 the first pathogenic mutation was 
described. Since then more than 150 mutations have been reported and POLG gene is 
considered a hot-spot for mutations in mitochondrial diseases [21]. 
3.1.2. POLG2  
MtDNA is replicated by DNA polymerase gamma, which is composed of a 140-kD catalytic 
subunit (encoded by POLG) and a 55-kD accessory subunit (POLG2). The accessory subunit 
increases enzyme processivity therefore it is not surprising that failure in this processivity 
leads to the accumulation of mtDNA deletions. 
The POLG2 gene is located at chromosome 17, comprises 8 exons spanning 19.28 Kb. In 2006 
the first pathogenic mutation was described as being a cause of adPEO [22]. Since then, 10 
mutations in POLG2 have been reported. 
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3.1.3. C10orf2 (Twinkle) 
The mitochondrial helicase/primase encoded by C10orf2 gene is also responsible for the 
adPEO [23]. Mutations in C10orf2 may be of variable severity, being associated with clinical 
presentations ranging from late-onset ‘‘pure’’ PEO, to PEO complicated by proximal limb 
and facial muscle weakness, dysphagia and dysphonia, mild ataxia, and peripheral 
neuropathy. Recessive C10orf2 mutations were also described in patients with 
hepatocerebral form of MDS [24].  
The C10orf2 gene is located at chromosome 10; it comprises 5 exons spanning 6.38 kb. The 
first pathogenic mutation was reported in 2001 [23] to be associated with PEO and since 
then 45 pathogenic mutations have been reported. 
3.2. Genes involved in the synthesis and supply of nucleotide pools 
3.2.1. SLC25A4 
This gene, coding for the muscle-heart-specific mitochondrial adenine nucleotide 
translocator (ANT) is a member of the mitochondrial carrier subfamily of solute carrier 
protein genes [25]. ANT is the most abundant mitochondrial protein and in its functional 
state, it is a homodimer of 30-kD subunits embedded asymmetrically in the inner 
mitochondrial membrane. The dimer forms a gated pore through which ADP is moved from 
the matrix into the cytoplasm. There are three recognized isoforms of this protein. 
Mutations in this gene have been shown to be responsible for the adPEO and have been also 
associated with a relatively mild, slow progressive myopathy, with little or no 
extramuscular symptoms. 
The SLC25A4 gene was identified in 2000 [25], it is located at chromosome 4, comprises 4 
exons spanning 4.04 Kb. The first pathogenic mutations were described in 2000 and since 
then only seven mutations have been reported (most of them associated with PEO). 
3.2.2. SLC25A3 
The SLC25A3 gene codes for a mitochondrial phosphate carrier. A defect in this mitochondrial 
phosphate carrier has been described in two children with hypertrophic cardiomyopathy, 
muscular hypotonia, severe growth retardation and death in the first year of life [26]. 
The gene is located at chromosome 12, comprises 7 exons spanning 8.37 Kb. The first 
pathogenic mutations were described in 2007 [26] and since then only one more mutation 
has been reported. 
3.2.3. Tymp (ECGF1)  
The Tymp gene, responsible for MNGIE (Mitochondrial NeuroGastroIntestinal 
Encephalomyopathy), encodes the enzyme thymidine phosphorylase (TP), which is 
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involved in pyrimidines catabolism. Defects of TP result in systemic accumulation of 
thymidine and deoxyuridine, which leads to deoxynucleotide pool imbalance and mtDNA 
instability, resulting in the presence of multiple deletions and partial depletion of muscle 
mtDNA [27].  
The Tymp gene is located at chromosome 22 it comprises 10 exons spanning 4.3 kb. The first 
pathogenic mutations were described in 1999 [27] and since then 65 mutations have been 
described as being associated with MNGIE. 
3.2.4. TK2 
Thymidine kinase (TK2) is an intramitochondrial pyrimidine nucleoside kinase that 
phosphorylates deoxynucleotides (dNTPs), such as: deoxythymidine, deoxycytidine, and 
deoxyuridine, thereby participating in the salvage pathway of deoxynucleotide synthesis in 
the mitochondria [28]. Mitochondrial dNTPs pools arise either through active transport of 
cytosolic dNTP or through salvage pathways. Both pathways are essential for the replication 
of mtDNA, since the mitochondrion is unable to synthesize dNTPs de novo. Mutations in the 
TK2 gene on chromosome 16q22 affect primarily muscle tissue, with little or no effect on the 
liver, brain, heart, or skin. The typical manifestation of TK2 mutations is a severe, rapidly 
progressing myopathy of infantile or childhood onset. The disease course is rapidly 
progressive, leading to respiratory failure and death in months or years, but milder 
phenotypes with slower progression and longer survival have been reported [10]. Since the 
first mutation was described in 2001 [29], approximately 25 different pathogenic mutations 
in TK2 have been published so far, either as recessive homozygous or compound 
heterozygous mutations, and phenotypes may be explained by variable degrees of residual 
activity of the mutant enzymes. 
3.2.5. DGUOK 
Deoxyguanosine kinase is a 2-deoxyribonucleoside enzyme that catalyzes the first step of 
the mitochondrial deoxypurine salvage pathway, the phosphorylation of purine 
deoxyribonucleosides into the corresponding nucleotides deoxyguanosine and 
deoxyadenosine necessary for the maintenance of mitochondrial dNTPs pools [11,30]. The 
typical phenotype of mutations in the DGUOK gene, on chromosome 2p13, is characterized 
by neonatal onset of progressive liver disease and feeding difficulties, usually with 
neurological dysfunction (hypotonia, nystagmus, and psychomotor retardation), by the age 
of 3 months. Peripheral neuropathy and renal tubulopathy have occasionally been reported 
[31]. Depletion of mtDNA has been documented only in the liver and results in combined 
respiratory chain deficiencies in the liver, whereas the amount of mtDNA is usually normal 
in muscle and fibroblasts. Histological analyses of the liver biopsy show variable findings, 
typically microvacuolar steatosis, cholestasis, fibrosis, and cirrhosis. In most cases, there is a 
rapidly progressive liver disease and neurological deterioration, with death occurring by the 
age of 12 months or shortly thereafter [32]. The first pathogenic mutations was reported in 
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2001 [33], since then more than 80 affected patients from approximately 50 families have 
been reported, and over 40 different DGUOK mutations have been identified [10]. The 
infantile hepatocerebral form of MDS is the almost invariable clinical presentation. 
Genotype-phenotype correlation studies show that patients who harbor null mutations 
usually have early onset liver failure and significant neurological disease, including 
hypotonia, nystagmus, and psychomotor retardation, and death before two years of age. 
Patients carrying missense mutations usually have isolated liver disease, a better prognosis, 
and longer survival. 
3.2.6. RRM2B 
The RRM2B gene on chromosome 8q23 encodes the small subunit of p53-inducible 
ribonucleotide reductase, a heterotetrameric enzyme responsible for de novo conversion of 
ribonucleoside diphosphates into the corresponding deoxyribonucleoside diphosphates that 
are crucial for DNA synthesis [34]. The enzyme is the main regulator of the nucleotide pools 
in the cytoplasm, and its small subunit is expressed in postmitotic cells, where it  
probably has a key function in maintaining the mitochondrial dNTPs pools for mtDNA 
synthesis. Mutations in RRM2B usually result in hypotonia, lactic acidosis, failure to  
thrive, and tubulopathy in the first months of life. The disease has a rapid progression and 
leads to death in a few months. The associated complex phenotype suggests that the 
consequences of a defective mitochondrial dNTPs pools can vary dramatically depending 
on the residual amount of the functional enzyme. Recently, it has been shown that 
inactivating mutations in RRM2B also cause severe neonatal or infantile forms of mtDNA 
depletion, with profound reduction of mtDNA copy numbers in skeletal muscle [34]. The 
first pathogenic mutation was reported in 2007 [34] and since then 26 mutations have been 
described. 
3.2.7. MPV17 
The MPV17 gene is located on chromosome 2p23-p21 and encodes a mitochondrial inner 
membrane protein of unknown function recently recognized as responsible for mtDNA 
depletion. The clinical presentation is that of severe liver failure, hypoglycemia, growth 
retardation, neurological symptoms, and multiple brain lesions during the first year of life 
[35]. Marked mtDNA depletion in the liver is the molecular hallmark associated with 
multiple defects of respiratory chain complexes. Normal or mildly reduced levels of both 
mtDNA content and respiratory chain enzyme activities were also found in muscle [36]. 
Histological analyses of the liver have revealed swollen granular hepatocytes, 
microvesicular steatosis, and focal pericellular and periportal fibrosis. Since the first 
mutation was described in 2006 [37], about 15 different mutations have been reported in 
infantile-onset hepatocerebral syndrome and in Navajo neurohepatopathy, which is an 
autosomal recessive multisystem disorder found in the Navajo of the southwestern United 
States [30]. Three main subtypes are to be considered: infantile-onset (before 6 months) and 
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childhood-onset (before 5 years) forms with hypoglycemic episodes and severe progressive 
liver dysfunction requiring liver transplant, and a ‘classic’’ form with moderate hepatopathy 
and progressive sensorimotor axonal neuropathy. The three forms are also associated with 
variable degrees of demyelination in both the central and the peripheral nervous system.  
3.2.8. SUCLA2 and SUCLG1 
Succinyl CoA synthase is a mitochondrial matrix enzyme that catalyzes the reversible 
synthesis of succinate and ATP or GTP from succinyl-CoA and ADP in the tricarboxylic acid 
cycle. This enzyme is made up of two subunits, a and b, encoded by SUCLG1 on 
chromosome 2p11 and SUCLA2 on 13q12, respectively. Mutations in SUCLA2 and SUCLG1 
cause an encephalomyopathic form of infantile mtDNA depletion syndrome, but SUCLG1 
can also cause a very severe disorder with antenatal dysmorphisms, neonatal metabolic 
crisis, and early death, probably depending on the lower residual amount of the protein 
[38,39]. A useful diagnostic clue in Succinyl CoA synthase disorders of succinyl CoA 
synthase is a ‘‘mildly’’ elevated urinary methylmalonic acid, which is detected in all 
patients, and presence of tricarboxylic acid cycle intermediates (methylcitrate, lactate, 
carnitine esters, 3-hydroxyisovalericacid) in most cases. Some patients die as infants (sudden 
infant death syndrome), but some of them have a longer survival. The clinical features of 
patients with mutations in these genes include early childhood hypotonia, developmental 
delay, and almost invariably, progressive dystonia and sensorineural deafness. SUCLA2 and 
SUCLG1 mutations seem to disrupt an association between succinyl CoA synthase and 
mitochondrial nucleoside diphosphate kinase, resulting in an unbalanced mitochondrial 
dNTP pool and eventually, mtDNA depletion in muscle. The first pathogenic mutations 
were reported in 2005 [40] and 2007 [41] in SUCLA2 and SUCLG1, respectively and since 
then few mutations have been described. 
3.3. Genes involved in mitochondrial translation 
Mendelian diseases characterized by defective mitochondrial protein synthesis and 
combined respiratory chain defects have also been described in infants and are associated 
with mutations in nuclear genes that encode components of the translational machinery, 
such as those encoding elongation factors, aminoacyl-tRNA synthetases, or even mtDNA 
encoded tRNA [12]. Mitochondria contain a separate protein-synthesis machinery to 
produce the polypeptides encoded in mtDNA, and many mtDNA disease mutations affect 
this machinery. This group of disorders is highly heterogeneous and usually shares a 
combined disorder of respiratory chain complexes.  
3.3.1. Genes involved in mitochondrial translation factors 
3.1.1.1. PUS1  
The Pseudouridine synthase 1 (PUS1) gene on chromosome 12q24 encodes an enzyme 
that converts uridine into pseudouridine at several cytoplasmic and mitochondrial tRNA 
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positions and thereby improves translation efficiency in the cytosol as well as  
the mitochondrion. Thus, PUS1 is not part of the translation machinery, but it is required 
for protein synthesis because of its function in posttranscriptional modification of  
tRNA. Mutations in PUS1 are responsible for the rare myopathy, lactic acidosis, 
sideroblastic anemia syndrome and sometimes include mental retardation. The first 
pathogenic mutation was reported in 2004 [42] and since then few mutations have been 
described. 
3.1.1.2. TRMU 
The TRMU gene on chromosome 22q13 encodes an evolutionarily conserved protein 
involved in mitochondrial tRNA modification and is important for mitochondrial 
translation. Defects in tRNA 5-methylaminomethyl-2-thiouridylate methyltransferase 
(TRMU), a mitochondria specific enzyme that is required for the 2-thiolation on the wobble 
position of the tRNA anticodon, result in reduced steady-state levels of 3 tRNA (tRNALys, 
tRNAGln, and tRNAGlu) and consequently, impaired mitochondrial protein synthesis 
[43,44]. Recently, mutations in TRMU were detected in patients with acute liver failure in 
infancy [44].  
3.1.1.3. LRPPRC 
The LRPPRC gene is located on chromosome 2p21. Leucine-rich PPR-motif containing 
protein has been suggested to function together with heterogeneous nuclear 
ribonucleoprotein K and RNA polymerase in coupling the mitochondrial transcription and 
translation machineries [45]. Mutations in LRPPRC lead to the French-Canadian subtype of 
Leigh syndrome, associated with a profound deficiency of complex IV of the OXPHOS 
system [46]. Patients exhibit neonatal or infantile onset hypotonia and psychomotor delay, 
and bilateral hyperluciencies of basal ganglia, like other more common forms of Leigh 
syndrome. The first pathogenic mutation was reported in 2003 [46] and since then one more 
mutation has been described. 
3.1.1.4. TACO1 
TACO1 represents the first specific mammalian mitochondrial translational activator, 
opening the possibility to a new class of proteins controlling efficiency of mitochondrial 
translation. Mutations in TACO1, located on chromosome 17q.6, are responsible for a 
relatively late-onset Leigh syndrome (onset range 4-13 years) characterized by short stature, 
mental retardation with autistic-like features, and a slowly progressive array of motor 
symptoms related mainly to basal ganglia involvement [47,48]. Only one mutation was 
described to date [47].  
3.1.1.5. TUFM, TSFM and GFM1 
Another important player during mitochondrial protein biosynthesis is the group of 
elongation factors. The mitochondrial EF-Tu forms a ternary complex with tRNA and GTP 
and promotes the binding of tRNA to the ribosome. A few patients have been described as 
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having mutations in genes encoding components of the mitochondrial translation 
elongation machinery, including elongation factor EF-Tu (TUFM), EF-Ts (TSFM) and EFG1 
(GFM1). These patients have severe disease, presenting neonatal lactic acidosis and 
neurological impairment resembling Leigh syndrome, leading to early fatality. The first 
pathogenic mutations in these genes were reported recently [49,50,51] and since then few 
mutations have been described. 
3.1.1.6. MRPS16 and MRPS22  
Of all 81 human mitochondrial ribosomal proteins (MRPs), mutations have been found in 
only two, MRPS16 and MRPS22 [52,53]. Both defects resulted in a marked decrease in the 
12S rRNA transcript level, probably caused by impaired assembly of the mitoribosomal 
small subunit, generating unincorporated and unstable 12S rRNA. Indeed, lack of MRPs 
results in the failure to assemble parts of small subunits of the mitoribosome, and 
subsequent degradation of its components [54]. Clinical manifestations include agenesis of 
the corpus callosum, dysmorphism, hypertrophic cardiomyopathy, and fatal neonatal lactic 
acidosis. The first pathogenic mutations were reported in 2004 [52] and in 2007 [53], and 
since then few mutations have been described. 
3.3.2. Genes involved in mitochondrial aminoacyl tRNA synthetases 
3.3.2.1. RARS2, DARS2, and YARS2  
To guarantee fidelity in translation, it is important to attach the right amino acid to the 
tRNA and to ensure that the tRNA recognizes, through its anticodon, the correct codon in 
the ribosomal A-site. Incorporation of an incorrect amino acid into the nascent polypeptide 
could cause misfolding and production of defective or dominant interfering proteins. 
Amino acids are attached to tRNA by amino-acyl-tRNA synthetases, each of which is 
specific for a single amino acid. However, as there can be several codons and several 
different tRNA for a single amino acid, an amino-acyl-tRNA synthetase can ‘‘charge’’ 
several different tRNA. If this function is defective, certain codons will become ambiguous, 
resulting in the synthesis of misfolded proteins, which could aggregate to form inclusions 
and induce further protein misfolding. Mutations in the RARS2 and DARS2 were recently 
described [55,56,57] and are associated with severe encephalopathy with pontocerebellar 
hypoplasia and leukoencephalopathy with brain stem and spinal cord involvement and 
lactate elevation, respectively, with most patients showing onset between 2-15 years of age 
[56]. Very recently, mutations in the gene encoding the mitochondrial YARS2 have been 
associated with a clinical condition characterized by myopathy, lactic acidosis, and 
sideroblastic anemia [54].  
4. Diagnostic approaches for intergenomic communication disorders 
Suspicion of intergenomic communication disorders arising from clinical presentation may 
range from well defined syndromes to unspecific multisystemic phenotype, where 
neurological involvement is usually present.  
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Establishing a specific diagnosis in a patient with suspected mendelian disease is a 
challenging task that requires the integration of clinical assessments, family history, 
biochemical testing and histopathological examination. It is important to obtain the 
appropriate biochemical and/or clinical information before starting any molecular 
investigations so that molecular diagnosis can be successfully.  
Biochemical determination of mitochondrial respiratory chain complexes is important for 
delineating the molecular approach in particular in patients without a specific neurological 
syndrome. As mtDNA encodes for subunits of respiratory chain complexes I, III, IV and the 
ATP-synthase, mtDNA depletion causes a combined respiratory chain deficiency of all 
complexes, except complex II. Biochemical analysis of the muscle respiratory chain enzyme 
activities may, however, be normal, if skeletal muscle is not among the affected tissues, e.g., in 
MDS of the brain or liver. Southern analysis or quantitative real-time polymerase chain 
reaction are two methods that simultaneously detects mtDNA deletion(s) and quantify total 
mtDNA content. In both approaches, mtDNA amount is compared to a specific nuclear 
reference gene. A prerequisite for correct interpretation of mtDNA amount is to consider the 
dynamic nature of mtDNA amount in different ages and tissues, and therefore to establish 
carefully age-matched control materials [58]. A reduction in mtDNA copy number to 60-65% 
of age-matched controls has been established for an empirical cut-off level for MDS diagnosis, 
but especially in children, the reduction may be severe (80-90%). Biochemical data, such as 
lactate, pyruvate, alanine, organic acid profiles as well as neuroimaging findings are also 
important clues for the diagnosis of these disorders. Some diagnostic clues exist for specific 
gene defects: serum creatine kinase (CK) is elevated in TK2 defects, serum thymidine in TYMP 
defects and urine methylmalonic acid and methylcitrate in SUCLA2 and SUCLG1 defects [10]. 
The POLG gene seems to be the most frequently mutated nuclear gene in cases of 
mitochondrial disease therefore in cases of normal mtDNA testing and clinical signs such as 
nonspecific hypotonia, developmental delay, epilepsy and progressive liver disease POLG 
gene investigation should be considered. Valproate-induced liver toxicity in POLG and 
C10orf2-MDS emphasizes the importance of diagnosing these patients, who usually suffer 
from severe treatment-resistant epilepsy [59]. We suggest POLG analysis before valproate 
treatment for such children and adolescents, whose first epileptic attack develops to a status 
epilepticus of unknown cause. 
Based on our practice, we present a testing algorithm for establishing an accurate diagnosis 
for these diseases (Figure 2). 
5. Therapeutic considerations 
The management of mitochondrial disease is largely supportive as no curative therapy is 
available. Palliative/supportive treatment with vitamins, cofactors and respiratory 
substrates have been used, but with poor efficacy. In the last years several approaches have 
been tried and the enhancement of mitochondrial biogenesis has emerged as an exciting 
therapeutic possibility. The enhancement of mitochondrial biogenesis might restore 
mitochondrial function in a variety of other contexts.  
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Figure 2. Diagnostic algorithm for intergenomic communication disorders, based on clinical and 
biochemical information. 
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What has been noticed is that for every case there is a different strategy. For example liver 
transplantation may be beneficial to patients with hepatopathy caused by DGUOK 
mutations if no neurological symptoms have developed. However, significant hypotonia, 
psychomotor retardation or nystagmus should be contraindications for the liver 
transplantation [60]. In patients with MPV17, liver transplantation has increased quality and 
years to life for some patients [61,62], but the patients have developed neurological 
symptoms. Some children with POLG mutations have received a liver transplant after 
valproate-induced liver failure, and although it has rescued their liver function, neurological 
outcome has been unfavorable [63,64]. 
In patients with MPV17 mutations, a controlled diet avoiding hypoglycemias were 
suggested to slow down the progression of liver impairment and be useful in supportive 
care [65]. Some improvement of liver functions in a patient with MPV17 mutations was 
gained by treating them with succinate or coenzyme-Q10 together with a lipid-rich diet [66]. 
Further studies with larger patient materials and longer follow-up time are needed to 
confirm, if these dietary interventions were beneficial, and could be recommended. In 
MNGIE, correlation between plasma thymidine levels and the severity of the phenotype has 
been observed [67]. Therefore, attempts to reduce the circulating nucleotide levels could 
result in disease improvement. Enzyme replacement therapy has been applied for MNGIE: 
infusion of platelets from healthy donors to patients with MNGIE reduced their circulating 
thymidine and deoxyuracile levels, and partially restored TP activity. The limitation of this 
therapy was the short half-life of platelets [68]. Allogenic stem cell transfusions have been 
given to two patients with MNGIE [69]. Although more experience is needed to illustrate 
the clinical benefit of that treatment, it opens up a possibility of treatment for disorders of 
the nucleoside metabolism. In MNGIE, also continuous ambulatory peritoneal dialysis has 
been used to reduce the thymidine levels, and this resulted in improvement of the 
symptoms during 3-year follow-up time [70]. Good animal models will enable testing these 
hypotheses in vivo. 
6. Conclusive remarks 
The diagnostic process in nuclear disorders of oxidative metabolism is not too different from 
that employed for other diseases and includes patient and family history, physical and 
neurologic examination, routine and special laboratory tests, muscle biopsy for morphology 
and biochemistry, and molecular genetics screening [71]. A mitochondrial disease 
manifesting at or soon after birth is more likely to be associated with nDNA than with 
mtDNA mutations, but until very recently, our profound ignorance regarding the 
mechanisms underlying mitochondrial gene transcription and translation and the complex 
interaction between the ‘‘2 genomes’’ has limited our diagnostic power. Mitochondrial DNA 
deletion and depletion syndromes, and disturbances in the mitochondrial translation 
machinery have become an increasingly important cause of a wide spectrum of infantile and 
childhood-onset multisystem disorders. Depletion syndromes could result from any 
imbalance of the mitochondrial dNTPs pools available for mtDNA replication, as well as 
abnormalities in either the mitochondrial helicase or DNA polymerase. Consistent with the 
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different phenotypes, mtDNA depletion may affect specific tissue (most commonly, brain 
and muscle or liver) or multiple organs, including the heart and the kidney. Predictably, 
affected tissues show paucity of mtDNA-encoded translation products and multiple 
respiratory chain defects. More than 75% of these patients had onset during the first year of 
life, and the disease was rapidly fatal in most cases [3,72,]. Moreover, though the 
components of the complicated mitochondrial protein-synthesis machinery are exclusively 
nuclear encoded, the majority of mutation affects correct translation of mtDNA-encoded 
subunits of the OXPHOS system and accounts for a still undetermined number of genetic 
defects. Indeed, there is still limited information on the many mitoribosomal proteins; the 
several tRNA maturation enzymes; the aminoacyl-tRNA synthetases; the translation 
initiation, elongation, and termination factors; and the predictably larger number of 
unidentified factors needed for ribosome assembly [43,73]. 
The increasing number of nuclear governed mitochondrial diseases and its associated genes 
continues to increase the diversity of the genetic and clinical phenotypic heterogeneity of 
this group of disorders. Identifying the causative genes is not only important for adequate 
genetic counseling and prenatal diagnosis but also to have a better understanding of the 
disease pathophysiology leading to better therapy options. The increasing number of genes 
involved is a driving force for the development of high throughput strategies. The recent 
advances on sequencing technology will facilitate the molecular investigations of genes 
associated with mtDNA disorders in general. Reports concerning the use of next generation 
sequencing for the diagnosis of mitochondrial disorders are emerging [74,75,76]. In a recent 
report the use of target NGS for mitochondrial disorders proved its efficiency in clinical 
diagnosis as for 55% of the studied patients a clear molecular etiology was found. As more 
studies are reported the importance of applying this technology will be highlighted.  
The problems faced by patients with mitochondrial respiratory chain disease are 
particularly severe. Diagnosis is difficult, treatment is largely ineffective, genetic counseling 
and prenatal diagnoses are uncertain or unavailable and the prognosis is unpredictable. 
Because diagnosis is imperfect and laborious, many patients undergo a whole battery of 
unnecessary investigations during the diagnostic process. Accurate focused diagnosis will 
save time, money and distress. Only by understanding the molecular genetic basis of these 
disorders, whether nuclear or mitochondrial, will any progress be made. Furthermore this 
will help patients, but will also lead to fundamental advances in our understanding of 
mitochondrial biology. Identification of new disease-causing gene(s) will hopefully provide 
insights towards novel therapeutic strategies. 
Chapter highlights 
- The chapter focus on diseases of intergenomic communication disorders mainly the 
ones involved in mtDNA integrity and mitochondrial protein synthesis 
- Disorders affecting mtDNA stability lead to multiple deletions or depletion of mtDNA 
- This group of disorders can affect a variety of organ with variable ages of onset 
- POLG is frequently mutated being a hotspot for mitochondrial disease 
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- Diagnosis is difficult and laborious due to the increasing number of genes involved 
- Therapy in mainly palliative however novel strategies are emerging 
- Due to the increasing number of genes involved novel diagnostic strategies are 
emerging to optimize the diagnosis offered to these families 
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